<DOC>
	<DOCNO>NCT00039377</DOCNO>
	<brief_summary>This phase II trial study well give imatinib mesylate together chemotherapy peripheral stem cell transplantation work treat patient newly diagnose acute lymphoblastic leukemia . Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Imatinib mesylate may stop growth cancer cell block enzymes necessary cancer cell growth . Giving imatinib mesylate together chemotherapy peripheral stem cell transplantation may effective treatment acute lymphoblastic leukemia .</brief_summary>
	<brief_title>Chemotherapy , Imatinib Mesylate , Peripheral Stem Cell Transplantation Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine activity imatinib mesylate ( Gleevec ) prolong disease-free survival ( DFS ) overall survival acute lymphoblastic leukemia ( ALL ) patient ( 9 ; 22 ) . II . Determine ability imatinib mesylate ( Gleevec ) produce maintain BCR-ABL-negative status , judge real-time-polymerase chain reaction ( RT-PCR ) follow sequential chemotherapy , imatinib mesylate ( Gleevec ) transplantation . III . Determine feasibility collect adequate peripheral blood stem cell autologous transplantation follow imatinib mesylate ( Gleevec ) therapy . IV . Study safety efficacy autologous peripheral stem cell transplantation follow therapy imatinib mesylate ( Gleevec ) . V. Study safety efficacy allogeneic stem cell transplantation follow therapy imatinib mesylate ( Gleevec ) . VI . Study safety efficacy imatinib mesylate ( Gleevec ) administer allogeneic autologous stem cell transplant . OUTLINE : COURSE I ( remission induction ) : Patients receive 1 course front-line induction therapy Cancer Leukemia Group B ( CALGB ) /Southwest Oncology Group ( SWOG ) protocol prior enrollment . COURSE II ( imatinib mesylate ) : Patients receive imatinib mesylate orally ( PO ) twice daily day 1-28 . COURSE III ( CNS prophylaxis ) : Within 7 day complete course II , patient receive methotrexate intrathecally ( IT ) , methotrexate intravenously ( IV ) 3 hour , vincristine sulfate IV day 1 , 8 , 15 ; methotrexate PO every 6 hour day 1-2 , 8-9 , 15-16 ; leucovorin calcium IV day 2 , 9 , 16 ; leucovorin calcium PO every 6 hour day 3 , 4 , 10 , 11 , 17 , 18 . COURSE IV ( imatinib mesylate ) : After blood count recover completion course III , patient receive imatinib mesylate course II . COURSE V : Patients undergo allogeneic peripheral blood stem cell transplantation ( PBSCT ) , autologous PBSCT , PBSCT . COURSE Va ( allogeneic PBSCT patient human leukocyte antigen [ HLA ] -matched sibling donor ) : Beginning 3-10 day completion course IV , patient HLA-matched sibling donor undergo total body irradiation ( TBI ) 2-3 time daily day -7 -4 . Patients receive etoposide IV 4 hour day -3 . Patients undergo PBSCT day 0 . Patients receive graft-vs-host disease prophylaxis tacrolimus IV continuously day -1 56 ( IV continuously day -1 14 PO IV every 12 hour day 15-56 ) follow taper . Patients also receive methotrexate IV day 1 , 3 , 6 , filgrastim subcutaneously ( SC ) begin day 4 continue blood count recover . COURSE Vb ( autologous PBSCT patient without HLA-matched sibling donor ) : Beginning 3-10 day completion course IV , patient without HLA-matched sibling donor receive etoposide IV continuously cytarabine IV 2 hour day 1-4 . Patients also receive filgrastim SC begin day 14 continue PBSC collection complete . Patients receive imatinib mesylate PO twice daily begin completion PBSC collection continue 3 day PBSCT . Patients undergo TBI 2-3 time daily day -8 -5 . Patients receive etoposide IV 4 hour day -4 cyclophosphamide IV 2 hour day -2 . Patients undergo PBSCT day 0 . Patients receive filgrastim SC begin day 0 continue blood count recover . COURSE Vc ( transplantation patient transplant candidate ) : Beginning 3-10 day completion course IV , patient candidate PBSCT receive etoposide IV 4 hour cytarabine IV 2 hour day 1-4 . Patients also receive filgrastim SC twice day begin day 14 continue blood count recover . COURSE VI : Patients receive imatinib mesylate PO twice daily begin day 30 post transplantation day 30 transplantation receive continue least 1 year patient 2 consecutive negative reverse transcriptase-polymerase chain reaction assay least 3 month apart relapse . After completion study treatment , patient follow monthly 1 year , every 3 month 2 year , every 6 month 2 year , yearly 5 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>Unequivocal histologic diagnosis ALL Detection ( 9 ; 22 ) ( q34 ; q11 ) 3way variant metaphase cytogenetics BCRABL positive molecular analysis ( RTPCR fluorescence situ hybridization [ FISH } ) Prior Therapy : Complete partial remission follow one course induction chemotherapy intensive 4 5 drug regimen ( without imatinib mesylate ) CALGB SWOG ALL protocol previously untreated ALL patient Note : The double induction regimen SWOG S0333 consider one course induction chemotherapy purpose eligibility criterion ; therefore , patient S0333 may eligible study complete entire double induction regimen Complete partial remission follow one course therapy standard induction regimen ( without imatinib mesylate ) without prior enrollment cooperative group frontline protocol ; instance , documentation Philadelphia chromosome ( Ph ) + positivity may occur outside CALGB SWOG laboratory Note : CALGB institution must enroll patient CALGB 9862 submission initial sample companion trial must occur time enrollment CALGB C10001 ; enrollment companion study CALGB 8461 9665 require No six week prior imatinib mesylate induction therapy study enrollment Nonpregnant nonnursing ; treatment protocol would expose unborn child significant risk ; woman men reproductive potential agree use effective mean birth control contraception continue three month last dose imatinib mesylate ( Gleevec ) allow complete clearance drug principle metabolites body ; woman childbearing potential , pregnancy test require study entry</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>